- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS
June 8th 2021, 7:25pm
The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Pimitespib Doubles PFS in Advanced Refractory GIST
June 8th 2021, 6:25pm
The heat shock protein 90 inhibitor pimitespib led to a significant improvement in progression-free survival and prolongation in overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib.
Dr. Ramalingam on Updated Data With Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
June 8th 2021, 5:55pm
Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.
Teclistamab Demonstrates Encouraging Efficacy, Safety at the RP2D in Relapsed/Refractory Multiple Myeloma
June 8th 2021, 5:50pm
Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL
June 8th 2021, 5:45pm
C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Men With African Ancestry Less Likely to Receive Early Genomic Profiling in Prostate Cancer
June 8th 2021, 5:34pm
Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.
Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors
June 8th 2021, 5:32pm
The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.
TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer
June 8th 2021, 4:39pm
Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.
KCd Consolidation Does Not Show Noninferiority to ASCT in Transplant-Eligible, Newly Diagnosed Myeloma
June 8th 2021, 4:25pm
The 2-year progression free survival achieved with carfilzomib, cyclophosphamide, and dexamethasone consolidation did not prove to be noninferior to up-front autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma, although the margin is small.
Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC
June 8th 2021, 3:45pm
Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
Regorafenib/Avelumab Combo Elicits Modest Activity in Heavily Pretreated Biliary Tract Cancer
June 8th 2021, 1:54pm
The addition of regorafenib to avelumab demonstrated modest anti-tumor responses and survival benefit in patients with heavily pretreated biliary tract cancer.
C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL
June 8th 2021, 1:40pm
The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC
June 8th 2021, 12:18am
The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC
June 7th 2021, 11:57pm
Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.
Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST
June 7th 2021, 10:07pm
John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.
Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC
June 7th 2021, 10:01pm
Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.
Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma
June 7th 2021, 9:55pm
Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.
Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies
June 7th 2021, 9:30pm
Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.
Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL
June 7th 2021, 9:30pm
Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.
Pembrolizumab Plus Gemcitabine/Hypofractionated Radiotherapy Demonstrates Promising Efficacy in Muscle-Invasive Bladder Cancer
June 7th 2021, 9:22pm
Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.